Antiproliferative Effects of Tyrosine Kinase Inhibitors (Tyrphostins) on Human Bladder and Renal Carcinoma Cells

1995 ◽  
Vol 59 (6) ◽  
pp. 675-680 ◽  
Author(s):  
Netta Sion-Vardy ◽  
Daniel Vardy ◽  
Ulrich Rodeck ◽  
Csaba Kari ◽  
Robert M. Levin ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Renal Carcinoma ◽  
Kinase Inhibitors ◽  
Carcinoma Cells ◽  
Human Bladder ◽  
Antiproliferative Effects ◽  
Renal Carcinoma Cells

MP35-08 TYROSINE-KINASE INHIBITORS TREATMENT INDUCES IL-6 SECRETION ON RENAL CARCINOMA CELLS

2014 ◽  
Vol 191 (4S) ◽  
Author(s):  
Kei Ishibashi ◽  
Yoshiyuki Kojima ◽  
Tobias Haber ◽  
Joachim W. Thüroff ◽  
Walburgis Brenner
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Renal Carcinoma ◽  
Kinase Inhibitors ◽  
Carcinoma Cells ◽  
Renal Carcinoma Cells

scholarly journals Cooperative Blockade of CK2 and ATM Kinases Drives Apoptosis in VHL-Deficient Renal Carcinoma Cells through ROS Overproduction

Cancers ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 576
Author(s):  
Sofia Giacosa ◽  
Catherine Pillet ◽  
Irinka Séraudie ◽  
Laurent Guyon ◽  
Yann Wallez ◽  
...  
Keyword(s):  
High Throughput Screening ◽  
Renal Carcinoma ◽  
Kinase Inhibitors ◽  
Ex Vivo ◽  
Cancer Therapeutics ◽  
Carcinoma Cells ◽  
Wild Type ◽  
Cell Renal Cell Carcinoma ◽  
Von Hippel Lindau ◽  
Renal Carcinoma Cells

Kinase-targeted agents demonstrate antitumor activity in advanced metastatic clear cell renal cell carcinoma (ccRCC), which remains largely incurable. Integration of genomic approaches through small-molecules and genetically based high-throughput screening holds the promise of improved discovery of candidate targets for cancer therapy. The 786-O cell line represents a model for most ccRCC that have a loss of functional pVHL (von Hippel-Lindau). A multiplexed assay was used to study the cellular fitness of a panel of engineered ccRCC isogenic 786-O VHL− cell lines in response to a collection of targeted cancer therapeutics including kinase inhibitors, allowing the interrogation of over 2880 drug–gene pairs. Among diverse patterns of drug sensitivities, investigation of the mechanistic effect of one selected drug combination on tumor spheroids and ex vivo renal tumor slice cultures showed that VHL-defective ccRCC cells were more vulnerable to the combined inhibition of the CK2 and ATM kinases than wild-type VHL cells. Importantly, we found that HIF-2α acts as a key mediator that potentiates the response to combined CK2/ATM inhibition by triggering ROS-dependent apoptosis. Importantly, our findings reveal a selective killing of VHL-deficient renal carcinoma cells and provide a rationale for a mechanism-based use of combined CK2/ATM inhibitors for improved patient care in metastatic VHL-ccRCC.

Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines

2012 ◽  
Vol 138 (6) ◽  
pp. 907-916 ◽  
Author(s):  
Bénédicte Martin ◽  
Julien Edeline ◽  
Jean-Jacques Patard ◽  
Emmanuel Oger ◽  
Florence Jouan ◽  
...  
Keyword(s):  
Endothelial Cell ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Cell Lines ◽  
Renal Carcinoma ◽  
Kinase Inhibitors

Evaluating the Promiscuous Nature of Tyrosine Kinase Inhibitors Assessed in A431 Epidermoid Carcinoma Cells by Both Chemical- and Phosphoproteomics

2014 ◽  
Vol 9 (7) ◽  
pp. 1490-1498 ◽  
Author(s):  
Piero Giansanti ◽  
Christian Preisinger ◽  
Kilian V. M. Huber ◽  
Manuela Gridling ◽  
Giulio Superti-Furga ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Kinase Inhibitors ◽  
Carcinoma Cells ◽  
Epidermoid Carcinoma
Sign in / Sign up

Export Citation Format

Share Document